Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Lazaro Gamio/Axios

Heading into the 2019 college football season, Clemson and Alabama have once again separated themselves from the pack.

Driving the news: The two schools battled for the spotlight yesterday, as both held court — and traded barbs— during their respective conference's media days.

  • The backdrop: The two schools have met in the national championship three of the past four seasons, with Clemson holding a 2-1 advantage. (They met in the semifinals the other year and Alabama won).

The intrigue: Clemson won last year's title game in a dominating fashion, 44-16. As a result, the Tigers are the faces of college football and appear to have the upper hand over the Tide heading into this season in a way they haven't in years past.

  • As CBS Sports' Dennis Dodd puts it, "Alabama has lost before [but] losses like the one to Clemson tend to stand out as landmarks."

Clemson's outlook:

  • Good news: Trevor Lawrence and the Tigers will likely run away with the ACC again. They've won 34 of their past 36 conference games and outscored opponents by an average of 31+ points last season.
  • Bad news: While they're still loaded, the Tigers must replace four all-world defensive linemen (Clelin Ferrell, Christian Wilkins, Dexter Lawrence and Austin Bryant) along with their top three linebackers.

Alabama's outlook:

  • Good news: The Tide had the most efficient passing game in the nation last year and pretty much everyone is back … and a year older. QB Tua Tagovailoa's top two targets, Jerry Jeudy and Henry Ruggs III, are both elite NFL prospects.
  • Bad news: This is one of Coach Nick Saban's least experienced teams. Plus, they have to play Auburn at their place, where they've lost two of their previous three meetings.

P.S. ... Five of the 10 best players in the country play for either Clemson or Alabama, according to SI's recently released rankings. No other school has more than one player in the top 25, let alone the top 10.

  1. Trevor Lawrence, QB (Clemson)
  2. Tua Tagovailoa, QB (Alabama)
  3. Jonathan Taylor, RB (Wisconsin)
  4. Jerry Jeudy, WR (Alabama)
  5. Derrick Brown, DL (Auburn)
  6. Grant Delpit, S (LSU)
  7. Travis Etienne, RB (Clemson)
  8. Rondale Moore, WR (Purdue)
  9. Chase Young, DL (Ohio State)
  10. Raekwon Davis, DL (Alabama)

Go deeper

Biden explains justification for Syria strike in letter to Congress

Photo: Chris Kleponis/CNP/Bloomberg via Getty Images

President Biden told congressional leadership in a letter Saturday that this week's airstrike against facilities in Syria linked to Iranian-backed militia groups was consistent with the U.S. right to self-defense.

Why it matters: Some Democrats, including Sens. Tim Kaine (D-Va.) and Chris Murphy (D-Conn.) and Rep. Ro Khanna (D-Calif.), have criticized the Biden administration for the strike and demanded a briefing.

5 hours ago - Health

FDA authorizes Johnson & Johnson's one-shot COVID-19 vaccine for emergency use

Photo: Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images

The Food and Drug Administration on Saturday issued an emergency use authorization for Johnson & Johnson's one-shot coronavirus vaccine.

Why it matters: The authorization of a third coronavirus vaccine in the U.S. will help speed up the vaccine rollout across the country, especially since the J&J shot only requires one dose as opposed to Moderna and Pfizer-BioNTech's two-shot vaccines.

Updated 5 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios